July 23, 2018What's New
This past week, Dr. Mitchel presented at the Rare Disease Symposium, supported by the Westchester Biotech Project and Hosted by Iona College. His presentation was entitled: Novel Approaches to Clinical Research. The Westchester Biotech Project, a not-for-profit created to foster scientific research and collaboration by researchers, engineers, and data scientists, is working to create the Rare Disease Research Hub. It plans to establish a bio-incubator that would house tenant startups, as well as a venture fund that would invest in up to 12 startups.
Not only has Target Health obtained multiple orphan drug designations for our clients, but also contributed to FDA and EMA marketing approvals. Here are some examples and more to come:
Alagille Syndrome; Behcet's disease; Burn progression in hospitalized patients; Caries prevention, Head and neck cancer; Cushing's syndrome secondary to ectopic ACTH secretion; Debridement in hospitalized patients with 3rd degree burns; Dravet syndrome; Edema-related effects in hospitalized patients with 3rd degree burns; Fibrolamellar Carcinoma (FLC); Fungal infections; Gaucher disease; Growth hormone;Hereditary angioedema; Hodgkin's Lymphoma ; Intradialytic Hypotension (Symptomatic hypotension in the immediate post-dialytic period); Invasive Aspergillus Infections; Multiple myeloma; Osteonecrosis of the jaw; Ovarian cancer; Rabies; Scleroderma.
For more information about Target Health contact Warren Pearlson (212-681-2100 ext. 165). For additional information about software tools for paperless clinical trials, please also feel free to contact Dr. Jules T. Mitchel. The Target Health software tools are designed to partner with both CROs and Sponsors.
Joyce Hays, Founder and Editor in Chief of On Target
Jules Mitchel, Editor